A multivalent DNA aptamer specific for the B-cell receptor on human lymphoma and leukemia

Long-term survival still eludes most patients with leukemia and non-Hodgkin’s lymphoma. No approved therapies target the hallmark of the B cell, its mIgM, also known as the B-cell receptor (BCR). Aptamers are small oligonucleotides that can specifically bind to a wide range of target molecules and offer some advantages over antibodies as therapeutic agents. Here, we report the rational engineering of aptamer TD05 into multimeric forms reactive with the BCR that may be useful in biomedical applications. Systematic truncation of TD05 coupled with modification with locked nucleic acids (LNA) increased conformational stability and nuclease resistance. Trimeric and tetrameric versions with optimized polyethyleneglycol (PEG) linker lengths exhibited high avidity at physiological temperatures both in vitro and in vivo. Competition and protease studies showed that the multimeric, optimized aptamer bound to membrane-associated human mIgM, but not with soluble IgM in plasma, allowing the possibility of targeting leukemias and lymphomas in vivo. The B-cell specificity of the multivalent aptamer was confirmed on lymphoma cell lines and fresh clinical leukemia samples. The chemically engineered aptamers, with significantly improved kinetic and biochemical features, unique specificity and desirable pharmacological properties, may be useful in biomedical applications.

[1]  Ying-Fon Chang,et al.  Tenascin-C Aptamers Are Generated Using Tumor Cells and Purified Protein* , 2001, The Journal of Biological Chemistry.

[2]  Andreas Petri,et al.  MicroRNA silencing in primates: towards development of novel therapeutics. , 2009, Cancer research.

[3]  P. Leder,et al.  Complete nucleotide sequence of the membrane form of the human IgM heavy chain. , 1990, Nucleic acids research.

[4]  J. McNamara,et al.  Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice. , 2008, The Journal of clinical investigation.

[5]  J. Rogers,et al.  Two mRNAs with different 3′ ends encode membrane-bound and secreted forms of immunoglobulin μ chain , 1980, Cell.

[6]  Seppo Ylä-Herttuala,et al.  Challenges in monoclonal antibody-based therapies , 2009, Annals of medicine.

[7]  Kemin Wang,et al.  Selection of aptamers for molecular recognition and characterization of cancer cells. , 2007, Analytical chemistry.

[8]  S. Jayasena.  Aptamers: an emerging class of molecules that rival antibodies in diagnostics. , 1999, Clinical chemistry.

[9]  Z. Paroo,et al.  Biodistribution of phosphodiester and phosphorothioate siRNA. , 2004, Bioorganic & medicinal chemistry letters.

[10]  D. Scheinberg,et al.  Conscripts of the infinite armada: systemic cancer therapy using nanomaterials , 2010, Nature Reviews Clinical Oncology.

[11]  J. Stenvang,et al.  MicroRNAs as targets for antisense-based therapeutics , 2008, Expert opinion on biological therapy.

[12]  D. Shangguan,et al.  Aptamer Directly Evolved from Live Cells Recognizes Membrane Bound Immunoglobin Heavy Mu Chain in Burkitt's Lymphoma Cells*S , 2007, Molecular & Cellular Proteomics.

[13]  T. Waldmann,et al.  Antibody-based therapy of leukaemia , 2009, Expert Reviews in Molecular Medicine.

[14]  E. Holly,et al.  Expert Review of Non-Hodgkin’s Lymphomas in a Population-Based Cancer Registry , 2004, Cancer Epidemiology Biomarkers & Prevention.

[15]  Weihong Tan,et al.  Optimization and Modifications of Aptamers Selected from Live Cancer Cell Lines , 2007, Chembiochem : a European journal of chemical biology.

[16]  D. Boturyn,et al.  Tumor targeting with RGD peptide ligands-design of new molecular conjugates for imaging and therapy of cancers. , 2007, Anti-cancer agents in medicinal chemistry.

[17]  L. Gold,et al.  Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. , 1990, Science.

[18]  J. Cambier,et al.  Membrane immunoglobulin and its accomplices: new lessons from an old receptor 1 , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[19]  R. Warnke,et al.  Strategies for production of monoclonal anti-idiotype antibodies against human B cell lymphomas. , 1984, Journal of immunology.

[20]  Zhiwen Tang,et al.  Cell Specific Aptamer–Photosensitizer Conjugates as a Molecular Tool in Photodynamic Therapy , 2008, ChemMedChem.

[21]  Jonathan M Irish,et al.  Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells. , 2006, Blood.

[22]  Anton Hagenbeek,et al.  CD20-targeted therapy: the next generation of antibodies. , 2010, Seminars in hematology.

[23]  M. Reth,et al.  Regulation of B-cell proliferation and differentiation by pre-B-cell receptor signalling , 2009, Nature Reviews Immunology.

[24]  Weihong Tan,et al.  Molecular assembly for high-performance bivalent nucleic acid inhibitor , 2008, Proceedings of the National Academy of Sciences.

[25]  B. Hancock,et al.  Ten years of rituximab in NHL , 2009, Expert opinion on drug safety.

[26]  Michael Zuker,et al.  Mfold web server for nucleic acid folding and hybridization prediction , 2003, Nucleic Acids Res..

[27]  Volker A Erdmann,et al.  Application of locked nucleic acids to improve aptamer in vivo stability and targeting function. , 2004, Nucleic acids research.

[28]  B. Sullenger,et al.  Assembling OX40 aptamers on a molecular scaffold to create a receptor-activating aptamer. , 2008, Chemistry & biology.

[29]  D. Furst.  Serum immunoglobulins and risk of infection: how low can you go? , 2009, Seminars in arthritis and rheumatism.

[30]  P. Choyke,et al.  Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. , 2008, Nanomedicine.

[31]  J. Szostak,et al.  In vitro selection of RNA molecules that bind specific ligands , 1990, Nature.

[32]  Anton P. McCaffrey,et al.  Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors , 2009, Nature Biotechnology.

[33]  R. Kane,et al.  The design of polyvalent therapeutics. , 2008, Chemistry.

[34]  S. Denardo,et al.  Recombinant antibodies: from the laboratory to the clinic. , 2006, Cancer biotherapy & radiopharmaceuticals.